The potential of SMARCA4 and its mutually exclusive paralog SMARCA2 as therapeutic target has been already investigated in the case of lung cancer using an allosteric SMARCA4/SMARCA2 inhibitor [109]. Here, SMARCA2 is linked to lung carcinoma.